SAN DIEGO–(BUSINESS WIRE)–Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure?s entire preclinical portfolio of NLRP3 inhibitors.
Source: Genentech Acquires Jecure Therapeutics | Business Wire
